within Pharmacolibrary.Drugs.ATC.J;

model J01DD16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.145,
    Cl             = 0.0001933333333333333,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.030333333333333334,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DD16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cefditoren is an orally administered third-generation cephalosporin antibiotic used for the treatment of respiratory tract infections and skin infections caused by susceptible bacteria. It is approved in several countries for adult and pediatric use, especially for community-acquired pneumonia, acute exacerbations of chronic bronchitis, pharyngitis, and uncomplicated skin infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were obtained from studies in healthy adult volunteers after a single oral dose in the fasted state.</p><h4>References</h4><ol><li><p>Giuliano, S, et al., &amp; Tascini, C (2023). Cefditoren: a clinical overview. <i>The new microbiologica</i> 46(1) 9–17. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36853812/&quot;>https://pubmed.ncbi.nlm.nih.gov/36853812</a></p></li><li><p>Guay, DR (2001). Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. <i>Clinical therapeutics</i> 23(12) 1924–1923. DOI:<a href=&quot;https://doi.org/10.1016/s0149-2918(01)80147-8&quot;>10.1016/s0149-2918(01)80147-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11813929/&quot;>https://pubmed.ncbi.nlm.nih.gov/11813929</a></p></li><li><p>Igarashi, Y, et al., &amp; Matsumoto, K (2023). In vivo Pharmacokinetics/Pharmacodynamics Profiles for Appropriate Doses of Cefditoren pivoxil against S. pneumoniae in Murine Lung-Infection Model. <i>Pharmaceutical research</i> 40(7) 1789–1797. DOI:<a href=&quot;https://doi.org/10.1007/s11095-023-03539-4&quot;>10.1007/s11095-023-03539-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37253866/&quot;>https://pubmed.ncbi.nlm.nih.gov/37253866</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DD16;
